Reviewing Global Cord Blood Corporation (CO)’s and Sarepta Therapeutics Inc. (NASDAQ:SRPT)’s results

As Biotechnology companies, Global Cord Blood Corporation (NYSE:CO) and Sarepta Therapeutics Inc. (NASDAQ:SRPT) are our subject to compare. And more specifically their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Global Cord Blood Corporation 5 0.72 27.63M 0.27 21.25
Sarepta Therapeutics Inc. 95 65.70 70.63M -5.94 0.00

Table 1 highlights Global Cord Blood Corporation and Sarepta Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us the net margins, return on equity and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
Global Cord Blood Corporation 564,903,600.42% 0% 4.6%
Sarepta Therapeutics Inc. 74,253,574.43% -43.4% -26.7%

Volatility & Risk

Global Cord Blood Corporation’s 0.17 beta indicates that its volatility is 83.00% less volatile than that of S&P 500. Sarepta Therapeutics Inc.’s 1.97 beta is the reason why it is 97.00% more volatile than S&P 500.

Liquidity

The Current Ratio and a Quick Ratio of Global Cord Blood Corporation are 8.6 and 8.6. Competitively, Sarepta Therapeutics Inc. has 12.2 and 11.1 for Current and Quick Ratio. Sarepta Therapeutics Inc.’s better ability to pay short and long-term obligations than Global Cord Blood Corporation.

Analyst Recommendations

Global Cord Blood Corporation and Sarepta Therapeutics Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Global Cord Blood Corporation 0 0 0 0.00
Sarepta Therapeutics Inc. 0 0 9 3.00

Sarepta Therapeutics Inc. on the other hand boasts of a $184.4 average target price and a 65.56% potential upside.

Insider and Institutional Ownership

Roughly 18.2% of Global Cord Blood Corporation shares are owned by institutional investors while 95.9% of Sarepta Therapeutics Inc. are owned by institutional investors. Global Cord Blood Corporation’s share owned by insiders are 49.6%. Comparatively, Sarepta Therapeutics Inc. has 0.3% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Global Cord Blood Corporation 0.35% 1.4% -13.6% -7.37% -26.46% -10.39%
Sarepta Therapeutics Inc. -0.37% -4.95% 28.76% 14.56% 29.09% 36.4%

For the past year Global Cord Blood Corporation has -10.39% weaker performance while Sarepta Therapeutics Inc. has 36.4% stronger performance.

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2018, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership).

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company has a strategic alliance with Nationwide Children's Hospital for the advancement of microdystrophin gene therapy program under the research and option agreement, as well as Galgt2 gene therapy program under the license agreement; Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD under the research collaboration agreement; and CharleyÂ’s Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies under the research agreement. It also has a license agreement with the University of Western Australia for treatment of DMD by inducing the skipping of certain exons; collaboration and license agreement with Summit (Oxford) Ltd. for the development of ezutromid, an utrophin modulator which is in phase II clinical trials for the treatment of DMD; and a gene therapy research collaboration with Genethon to develop treatments for Duchenne muscular dystrophy. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.